Batch Record Review & Disposition Audit Readiness
Verify your batch record system is complete, contemporaneous, and inspection-ready from MBR to disposition
Overview
What's Inside
Batch production and control records are the single most scrutinised document set during FDA manufacturing inspections. Investigators use 21 CFR 211.188 to verify that every significant production step was documented with operator identity, dates, equipment IDs, material lot numbers, in-process results, and actual yields — and 21 CFR 211.192 to confirm the Quality Control Unit reviewed and approved every record before batch release. Gaps in batch records signal systemic failures that escalate rapidly.
This checklist is built from real FDA 483 observation patterns — including failure to review batch records before distribution, incomplete yield investigations that do not extend to other batches, contemporaneous documentation failures, missing second-person verifications for charge-in operations, electronic batch record audit trail gaps, and GDP non-compliance. Each section maps observations to specific CFR requirements, recommended corrective actions, and the evidence investigators expect to see.
It covers nine critical domains: master batch record governance, real-time recording practices and GDP compliance, in-process controls and yield documentation, QCU review scope and discrepancy investigation, equipment identification and process parameter monitoring, labeling and packaging reconciliation, operator training and competency, electronic batch record systems and data integrity, and batch record quality trending with record retention.
Why It Matters
Batch record deficiencies are among the most frequently cited 483 observations in pharmaceutical manufacturing. Over 60% of recent production system 483s cited electronic batch record failures — from missing audit trails to unchecked overrides. FDA investigators use batch record quality as a direct indicator of manufacturing control. Incomplete records, missing yield investigations, and failure to extend discrepancy investigations to other batches are reliable predictors of warning letters.
What's Covered
Sections in this checklist
- Master batch record control, version management, and issuance procedures
- Contemporaneous documentation, real-time recording practices, and GDP compliance
- In-process control testing, sampling, and acceptance criteria documentation
- Yield calculation, material reconciliation, and discrepancy investigation
- Quality Unit production record review scope, completeness, and batch disposition
- Equipment identification, process parameter monitoring, and calibration records
- Labeling control records, packaging component reconciliation, and line clearance
- Operator training, competency assessment, and personnel qualification
- Electronic batch record systems, audit trails, data integrity, and record retention
Who It's For
Target roles
Regulatory Basis
21 CFR 211.188, 21 CFR 211.192, 21 CFR 211.100, 21 CFR 211.101, 21 CFR 211.103, 21 CFR 211.110, 21 CFR Part 11, ICH Q7, ICH Q10, EU GMP Chapter 4, FDA Compliance Program 7356.002
Download Batch Record Review & Disposition Audit Readiness
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Related Checklists
Process Validation Lifecycle Audit Readiness
Comprehensive 150+ point audit checklist for pharmaceutical process validation covering the FDA three-stage lifecycle model — Process Design (Stage 1), Process Qualification (Stage 2), and Continued Process Verification (Stage 3) — plus revalidation triggers, in-process controls, microbiological contamination controls, and validation documentation aligned with the FDA 2011 Process Validation Guidance and 21 CFR 211.100/211.110.
In-Process Controls & Sampling Audit Readiness
Comprehensive 160-point audit checklist for pharmaceutical in-process controls covering CPP identification and control strategy, sampling plan design and statistical rationale, in-process testing methods and acceptance criteria, hold time validation, Quality Unit oversight, and trend analysis — grounded in real FDA 483 observation patterns under 21 CFR 211.110 and 21 CFR 211.100.
Equipment Cleaning Validation Audit Readiness
Comprehensive 140-point audit checklist for pharmaceutical equipment cleaning validation covering HBEL/MACO acceptance limit determination, worst-case equipment and product grouping, cleaning SOP adequacy, swab and rinse sampling strategy, analytical method validation, dirty and clean hold time studies, and lifecycle change control — grounded in real FDA 483 observation patterns under 21 CFR 211.67 and the EMA HBEL Guideline.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
